838 related articles for article (PubMed ID: 17676033)
1. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome.
Minegishi Y; Saito M; Tsuchiya S; Tsuge I; Takada H; Hara T; Kawamura N; Ariga T; Pasic S; Stojkovic O; Metin A; Karasuyama H
Nature; 2007 Aug; 448(7157):1058-62. PubMed ID: 17676033
[TBL] [Abstract][Full Text] [Related]
2. A novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene, in hyper-IgE syndrome.
Papanastasiou AD; Mantagos S; Papanastasiou DA; Zarkadis IK
Mol Immunol; 2010 Apr; 47(7-8):1629-34. PubMed ID: 20149460
[TBL] [Abstract][Full Text] [Related]
3. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups.
Jiao H; Tóth B; Erdos M; Fransson I; Rákóczi E; Balogh I; Magyarics Z; Dérfalvi B; Csorba G; Szaflarska A; Megarbane A; Akatcherian C; Dbaibo G; Rajnavölgyi E; Hammarström L; Kere J; Lefranc G; Maródi L
Mol Immunol; 2008 Nov; 46(1):202-6. PubMed ID: 18706697
[TBL] [Abstract][Full Text] [Related]
4. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.
Minegishi Y; Karasuyama H
Int Immunol; 2009 Feb; 21(2):105-12. PubMed ID: 19088064
[TBL] [Abstract][Full Text] [Related]
5. Clinical features, STAT3 gene mutations and Th17 cell analysis in nine children with hyper-IgE syndrome in mainland China.
Zhang LY; Tian W; Shu L; Jiang LP; Zhan YZ; Liu W; Zhao XD; Cui YX; Tang XM; Wang M; Wu DQ; Yang XQ
Scand J Immunol; 2013 Sep; 78(3):258-65. PubMed ID: 23659370
[TBL] [Abstract][Full Text] [Related]
6. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome.
Al Khatib S; Keles S; Garcia-Lloret M; Karakoc-Aydiner E; Reisli I; Artac H; Camcioglu Y; Cokugras H; Somer A; Kutukculer N; Yilmaz M; Ikinciogullari A; Yegin O; Yüksek M; Genel F; Kucukosmanoglu E; Baki A; Bahceciler NN; Rambhatla A; Nickerson DW; McGhee S; Barlan IB; Chatila T
J Allergy Clin Immunol; 2009 Aug; 124(2):342-8, 348.e1-5. PubMed ID: 19577286
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous manifestations of Hyper IgE syndrome.
Minegishi Y; Saito M
Allergol Int; 2012 Jun; 61(2):191-6. PubMed ID: 22441639
[TBL] [Abstract][Full Text] [Related]
8. Hyper-IgE syndrome.
Minegishi Y
Curr Opin Immunol; 2009 Oct; 21(5):487-92. PubMed ID: 19717292
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome.
Minegishi Y; Saito M
Ann N Y Acad Sci; 2011 Dec; 1246():34-40. PubMed ID: 22236428
[TBL] [Abstract][Full Text] [Related]
10. Hyper-IgE syndromes.
Grimbacher B; Holland SM; Puck JM
Immunol Rev; 2005 Feb; 203():244-50. PubMed ID: 15661034
[TBL] [Abstract][Full Text] [Related]
11. SH2-domain mutations in STAT3 in hyper-IgE syndrome patients result in impairment of IL-10 function.
Giacomelli M; Tamassia N; Moratto D; Bertolini P; Ricci G; Bertulli C; Plebani A; Cassatella M; Bazzoni F; Badolato R
Eur J Immunol; 2011 Oct; 41(10):3075-84. PubMed ID: 21792878
[TBL] [Abstract][Full Text] [Related]
12. STAT3 mutations in the hyper-IgE syndrome.
Holland SM; DeLeo FR; Elloumi HZ; Hsu AP; Uzel G; Brodsky N; Freeman AF; Demidowich A; Davis J; Turner ML; Anderson VL; Darnell DN; Welch PA; Kuhns DB; Frucht DM; Malech HL; Gallin JI; Kobayashi SD; Whitney AR; Voyich JM; Musser JM; Woellner C; Schäffer AA; Puck JM; Grimbacher B
N Engl J Med; 2007 Oct; 357(16):1608-19. PubMed ID: 17881745
[TBL] [Abstract][Full Text] [Related]
13. Hyper IgE (Job's) syndrome: a primary immune deficiency with oral manifestations.
Freeman AF; Domingo DL; Holland SM
Oral Dis; 2009 Jan; 15(1):2-7. PubMed ID: 19036057
[TBL] [Abstract][Full Text] [Related]
14. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3.
Paulson ML; Freeman AF; Holland SM
Curr Opin Allergy Clin Immunol; 2008 Dec; 8(6):527-33. PubMed ID: 18978467
[TBL] [Abstract][Full Text] [Related]
15. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.
Renner ED; Rylaarsdam S; Anover-Sombke S; Rack AL; Reichenbach J; Carey JC; Zhu Q; Jansson AF; Barboza J; Schimke LF; Leppert MF; Getz MM; Seger RA; Hill HR; Belohradsky BH; Torgerson TR; Ochs HD
J Allergy Clin Immunol; 2008 Jul; 122(1):181-7. PubMed ID: 18602572
[TBL] [Abstract][Full Text] [Related]
16. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity.
Buettner R; Huang M; Gritsko T; Karras J; Enkemann S; Mesa T; Nam S; Yu H; Jove R
Mol Cancer Res; 2007 Aug; 5(8):823-32. PubMed ID: 17699108
[TBL] [Abstract][Full Text] [Related]
17. Challenges of genetic counseling in patients with autosomal dominant diseases, such as the hyper-IgE syndrome (STAT3-HIES).
Spielberger BD; Woellner C; Dueckers G; Sawalle-Belohradsky J; Hagl B; Anslinger K; Bayer B; Siepermann K; Niehues T; Grimbacher B; Belohradsky BH; Renner ED
J Allergy Clin Immunol; 2012 Dec; 130(6):1426-8. PubMed ID: 22981789
[No Abstract] [Full Text] [Related]
18. Reduced expression of chemoattractant receptors by polymorphonuclear leukocytes in Hyper IgE Syndrome patients.
Mintz R; Garty BZ; Meshel T; Marcus N; Katanov C; Cohen-Hillel E; Ben-Baruch A
Immunol Lett; 2010 May; 130(1-2):97-106. PubMed ID: 20005258
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis.
Schimke LF; Sawalle-Belohradsky J; Roesler J; Wollenberg A; Rack A; Borte M; Rieber N; Cremer R; Maass E; Dopfer R; Reichenbach J; Wahn V; Hoenig M; Jansson AF; Roesen-Wolff A; Schaub B; Seger R; Hill HR; Ochs HD; Torgerson TR; Belohradsky BH; Renner ED
J Allergy Clin Immunol; 2010 Sep; 126(3):611-7.e1. PubMed ID: 20816194
[TBL] [Abstract][Full Text] [Related]
20. [Hyper-IgE syndrome with mutation in STAT3 gene - case report and literature review].
Heropolitańska-Pliszka E; Pietrucha B; Mikołuć B; Bernatowska E
Med Wieku Rozwoj; 2009; 13(1):19-25. PubMed ID: 19648655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
